Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and tolerability of intravenous zoledronic acid 4mg as an adjunct to standard therapies including conversion from pamidronate in breast cancer patients with metastatic bone lesions. A prospective, randomised, open-label, clinical study

Trial Profile

Efficacy and tolerability of intravenous zoledronic acid 4mg as an adjunct to standard therapies including conversion from pamidronate in breast cancer patients with metastatic bone lesions. A prospective, randomised, open-label, clinical study

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2009

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 22 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top